Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec;21(12):e4.
doi: 10.1634/theoncologist.2016-0262. Epub 2016 Nov 2.

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

Laura L Meijer  1   2 , Jisce R Puik  1   2 , Godefridus J Peters  1 , Geert Kazemier  2 , Elisa Giovannetti  1   3
Affiliations
Comment

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

Laura L Meijer et al. Oncologist. 2016 Dec.

Abstract

In this letter to the editor, the authors discuss the use of human equilibrative nucleoside transporter 1 (hENT-1) as a biomarker in patients with cholangiocarcinoma. They encourage standardization of techniques to evaluation expression of proteins such as hENT-1 and suggest additional studies investigating the active metabolites of gemcitabine, the use of liquid biopsies, and improved statistical methods.

PubMed Disclaimer

Comment in

  • In Reply.
    Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S. Brandi G, et al. Oncologist. 2016 Dec;21(12):e5-e6. doi: 10.1634/theoncologist.2016-0286. Epub 2016 Nov 2. Oncologist. 2016. PMID: 27807301 Free PMC article.

Comment on

References

    1. Brandi G, Deserti M, Vasuri F, et al. Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients. The Oncologist. 2016;21:600–607. - PMC - PubMed
    1. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–1940. - PubMed
    1. Greenhalf W, Ghaneh P, Neoptolemos JP, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014;106:djt347. - PubMed
    1. Ciccolini J, Serdjebi C, Peters GJ, et al. Pharmacokinetics and pharmacogenetics of gemcitabine as a mainstay in adult and pediatric oncology: An EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78:1–12. - PMC - PubMed
    1. Garajová I, Le Large TY, Giovannetti E, et al. The role of microRNAs in resistance to current pancreatic cancer treatment: Translational studies and basic protocols for extraction and PCR analysis. Methods Mol Biol. 2016;1395:163–187. - PubMed

LinkOut - more resources